Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor

Status: Completed
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Patients under clinical investigation of acromegaly disease with normal kidney function, liver function and hemoglobin levels.

Locations
Other Locations
Denmark
Department of Biomedical Sciences
Copenhagen
Time Frame
Start Date: 2019-08-13
Completion Date: 2023-11-28
Participants
Target number of participants: 25
Treatments
Other: GIP-A
Infusion of GIP-A alone as a study tool.
Placebo_comparator: Placebo
Saline
Sponsors
Collaborators: Odense University Hospital, Herlev and Gentofte Hospital, Aalborg University Hospital, Aarhus University Hospital, Rigshospitalet, Denmark
Leads: University of Copenhagen

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.